How should hemorrhagic cystitis caused by cyclophosphamide be treated?

Treatment of Cyclophosphamide-Induced Hemorrhagic Cystitis

For severe hemorrhagic cystitis from cyclophosphamide, immediately discontinue the drug and initiate aggressive hydration with forced diuresis and frequent bladder emptying; mesna can be used for prevention but has limited efficacy once hemorrhagic cystitis is established 1.

Immediate Management Steps

1. Discontinue Cyclophosphamide

The FDA label explicitly states to discontinue cyclophosphamide therapy in case of severe hemorrhagic cystitis 1. This is non-negotiable for severe cases, as urotoxicity can be fatal and may lead to bladder ulceration, necrosis, fibrosis, and contracture.

2. Aggressive Supportive Care

Implement aggressive hydration with forced diuresis and frequent bladder emptying to reduce bladder toxicity 1. This is the cornerstone of both prevention and treatment. The mechanism works by diluting and rapidly clearing the toxic metabolite acrolein from the bladder.

3. Medical and Surgical Support

For protracted cases of severe hemorrhagic cystitis, medical and/or surgical supportive treatment may be required 1. This can escalate to:

• Continuous bladder irrigation with saline
• Blood product transfusions for severe bleeding
• Intravesical therapies (see below)
• In extreme refractory cases, cystectomy may be necessary 2

Role of Mesna

Mesna has been used to prevent severe bladder toxicity 1, but its role is primarily prophylactic rather than therapeutic. The evidence on mesna efficacy is conflicting:

• A 2021 cohort study found that mesna did not prevent hemorrhagic cystitis and that the only influential factor was the cumulative cyclophosphamide dose 3
• The FDA label acknowledges mesna's use for prevention but does not strongly endorse it for established hemorrhagic cystitis 1

For prevention in future cyclophosphamide use: If cyclophosphamide must be resumed, ensure fluid infusion rates ≥125 mL/m²/h for doses <1500 mg/m²/day, and use mesna with vigorous hydration for doses ≥1500 mg/m²/day 4.

Advanced Interventions for Refractory Cases

When standard measures fail, consider:

1. Intravesical alum irrigation: Effective in controlling severe hematuria and avoiding cystectomy 5
2. Intravesical prostaglandins (carboprost): Continuous bladder irrigation with intermittent instillation has shown success in refractory cases 6
3. Total cystectomy with neobladder substitution: Reserved for life-threatening intractable hemorrhagic cystitis when all other measures fail 2

Monitoring Requirements

Check urinary sediment regularly for erythrocytes and other signs of urotoxicity 1. Before any future cyclophosphamide treatment, exclude or correct urinary tract obstructions, as the drug is contraindicated in patients with urinary outflow obstruction 1.

Critical Pitfalls to Avoid

• Do not continue cyclophosphamide in the setting of severe hemorrhagic cystitis—this can lead to fatal urotoxicity
• Do not rely solely on mesna for established hemorrhagic cystitis; it is primarily preventive
• Do not underestimate the risk: Hemorrhagic cystitis can occur with both short-term and long-term use, and even at low doses (documented after a single 600 mg/m² dose) 7
• Monitor long-term: All patients treated with cyclophosphamide should have periodic urinalysis for the duration of follow-up due to increased bladder cancer risk 8

Context from Guidelines

The EULAR and KDIGO guidelines emphasize that all patients treated with cyclophosphamide should have periodical urinalysis throughout follow-up 8. If hematuria is confirmed on urine microscopy and is not due to glomerulonephritis, a urology opinion must be sought 8.